Insulin lispro

What it is

Rapid-acting insulin analogs (insulin lispro, insulin aspart, insulin glulisine) are modified human insulin molecules engineered for faster absorption and shorter duration than regular human insulin. They are used as mealtime (“bolus”) insulin in patients with diabetes requiring insulin therapy. The amino acid modifications prevent self-association of insulin hexamers, allowing rapid monomer absorption from subcutaneous tissue.

Mechanism of action

Insulin binds the insulin receptor on multiple tissues, primarily liver, muscle, and adipose tissue, producing:

• Glucose uptake into muscle and adipose
• Suppression of hepatic glucose production
• Inhibition of lipolysis
• Promotion of glycogen, protein, and fat synthesis

Rapid-acting analogs onset within 5–15 minutes, peak around 60 minutes, and have duration of 3–5 hours — designed to match postprandial glucose elevation.

Approved indications

FDA-approved for treatment of type 1 and type 2 diabetes mellitus requiring insulin. Used in basal-bolus regimens (typically combined with a long-acting basal insulin), insulin pump therapy, and various other diabetes treatment paradigms.

Why this is out of scope at The Tide

Insulin therapy management is appropriately the domain of endocrinology and experienced primary care diabetes providers. Insulin requires careful titration based on glucose monitoring data, attention to hypoglycemia prevention, integration with diet and activity, and coordination of multiple insulin formulations. The Tide is a peptide-focused outpatient clinic and does not provide insulin management.

Patients with diabetes requiring insulin should receive comprehensive diabetes care from endocrinology or primary care with appropriate diabetes expertise.

Where to learn more

The American Diabetes Association Standards of Care, FDA prescribing information for specific insulin products, and your endocrinologist or primary care provider are the appropriate sources for insulin therapy information.